Cypherpunk Technologies Inc. Common Stock (CYPH) Stock Price

CYPHStock

$2.57+348.52%52W

Market Cap$273.61M

P/E—

PEG Ratio—

Div yield—

Beta1.15

CYPH Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)160.62%

Price vs S&P 500 (4W)-23.09%

VGM Score61.51

Book Value / Share (Quarterly)$1.29

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.32

Price vs S&P 500 (YTD)109.63%

Net Profit Margin (TTM)-2705.80%

EPS (TTM)$-0.10

10-Day Avg Trading Volume11.37M

EPS Excl Extra (TTM)$-0.10

EPS (Annual)$-1.80

ROI (Annual)-192.75%

Cash / Share (Quarterly)$0.07

P/E Basic Excl Extra (TTM)26.49x

ROA (Last FY)-137.52%

EBITD / Share (TTM)$-0.12

ROE (5Y Avg)-103.49%

Operating Margin (TTM)-2761.73%

Cash Flow / Share (Annual)$-0.52

P/B Ratio1.99x

P/B Ratio (Quarterly)0.47x

Net Income / Employee (Annual)$-11,259,200

Net Interest Coverage (TTM)-97.81x

ROA (TTM)-0.87%

EPS Incl Extra (Annual)$-1.80

Current Ratio (Annual)35.56x

Quick Ratio (Quarterly)78.88x

3-Month Avg Trading Volume8.56M

52-Week Price Return348.52%

P/E Incl Extra (TTM)26.49x

Revenue / Employee (TTM)$0

P/S Ratio (Annual)184.64x

Asset Turnover (Annual)0.01x

52-Week High$4.19

EPS Excl Extra (Annual)$-1.80

26-Week Price Return170.53%

Quick Ratio (Annual)35.55x

13-Week Price Return262.94%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)79.19x

Enterprise Value$269.33M

Asset Turnover (TTM)0.02x

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-2707.40%

Cash / Share (Annual)$0.17

3-Month Return Std Dev168.27%

Net Income / Employee (TTM)$-146,200

ROE (Last FY)-192.75%

Net Interest Coverage (Annual)-0.06x

EPS Basic Excl Extra (Annual)$-1.80

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.10

ROI (TTM)-0.92%

P/S Ratio (TTM)184.64x

Revenue / Share (Annual)$0.00

Forward P/E55.50x

Price vs S&P 500 (52W)332.98%

P/E Ratio (TTM)26.49x

Year-to-Date Return121.55%

5-Day Price Return-11.38%

EPS Normalized (Annual)$-1.80

ROA (5Y Avg)-82.39%

Net Profit Margin (Annual)-2705.80%

Month-to-Date Return-22.82%

EBITD / Share (Annual)$-1.87

Operating Margin (Annual)-2761.73%

ROI (5Y Avg)-103.49%

P/E Excl Extra (TTM)26.49x

EPS Basic Excl Extra (TTM)$-0.10

P/B Ratio (Annual)0.43x

Pretax Margin (TTM)-2707.40%

Book Value / Share (Annual)$1.83

Price vs S&P 500 (13W)260.26%

Beta1.15x

Revenue / Share (TTM)$0.00

ROE (TTM)-0.92%

52-Week Low$0.39

vGradeD

mGradeA

vgmGradeB

CYPH Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 12, 2026	-$0.03	-$0.02	+32.33%(+$0.01)
Q1 2026	May 14, 2026	—	-$0.46	—
Q3 2025	Nov 12, 2025	-$0.24	-$0.08	+66.67%(+$0.16)
Q2 2025	Aug 14, 2025	-$0.29	-$0.40	-37.93%(-$0.11)

CYPH Analyst Recommendations

Mar 2026

Jul 2026

Aug 2026

Sep 2026

2.17

4.14

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
CYPHCypherpunk Technologies Inc. Common Stock	D	—	A	184.6x	—	—	—	$2.57
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Cypherpunk Technologies Inc. Common Stock

Cypherpunk Technologies Inc develops novel therapies for cancer patients while maintaining a digital asset treasury concentrated in Zcash. The company combines oncology research and drug development with cryptocurrency asset management.

CYPH Next Earnings Report

Report dateNov 11, 2026

QuarterQ3 2026

Report timeBMO

Revenue estimate$16.20M

Also reporting on Nov 11, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

CYPH Insider Transactions

SellAug 26, 2026
DIETZ THOMAS JOHN
Director
Shares: 20,000Value: $34,400

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for August 2026

Companies in Related Industries

GEVOGevo, Inc.Industrial Chemicals
USNAUSANA Health Sciences IncPharmaceutical Preparations
ARTVArtiva Biotherapeutics, Inc. Common StockBiological Products
SRZNSurrozen, Inc. CommonBiological Products
AGENAgenus Inc.Biological Products
ALTOAlto Ingredients, Inc. Common StockIndustrial Chemicals
OCGNOcugen, Inc. Common StockBiological Products
XFORX4 Pharmaceuticals, Inc. Common StockBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.1

Buy

Consensus rating

52-Week Range

Low$0.39

High$4.19